Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile BTK C481S
Therapy Ibrutinib
Indication/Tumor Type chronic lymphocytic leukemia
Response Type resistant

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BTK C481S chronic lymphocytic leukemia resistant Ibrutinib Preclinical - Patient cell culture Actionable In a preclinical study, primary chronic lymphocytic leukemia cells derived from patients who acquired BTK C481S following Imbruvica (ibrutinib) treatment demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 30093506). 30093506
BTK C481S chronic lymphocytic leukemia resistant Ibrutinib Clinical Study - Cohort Actionable In a clinical study, BTK C481S was identified as an acquired mutation in patients with chronic lymphocytic leukemia who relapsed while on Imbruvica (ibrutinib), and was demonstrated to confer resistance to Imbruvica (ibrutinib) in preclinical studies (PMID: 24869598). 24869598
PubMed Id Reference Title Details
(24869598) Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. Full reference...
(30093506) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Full reference...